Data provides new insights into targeting the diverse pathobiology of Alzheimer’s disease, an approach spearheaded by the ADDF NEW YORK, Nov. 24, 2025 /PRNewswire/ — Today, Novo Nordisk released topline results from their phase 3 Evoke […]
Tag: Alzheimer's Drug Discovery Foundation
FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer’s Disease
Subcutaneous delivery increases accessibility and introduces potential for at-homeadministration, following model of diabetes and GLP-1 drugs NEW YORK, Aug. 29, 2025 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) today announced its approval of […]
Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder
The Lauder Family’s Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer’s Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ — It is with deep sorrow and profound admiration that the […]
Statement from the Alzheimer’s Drug Discovery Foundation (ADDF) on FDA Approval of the First Blood Test to Aid in Alzheimer’s Diagnosis
NEW YORK, May 16, 2025 /PRNewswire/ — Today, the FDA’s approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against Alzheimer’s disease. This is the first blood test authorized […]
Ocular Biomarkers: Key in Early Alzheimer’s Detection – ADDF’s Diagnostics Accelerator Study
New Findings: Blood and Ocular Biomarkers for Alzheimer’s Detection A groundbreaking study published in Alzheimer’s & Dementia sheds light on the future of Alzheimer’s diagnostics. The research suggests that blood biomarkers will likely become the […]
